Drug Trial Radar · NCT06360354
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Actual
Start
May 29, 2024
Primary completion
Oct 31, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Apr 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
Conditions
- Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Interventions
AnvumetostatDrug
Administered Orally
GemcitabineDrug
Administered IV
Nab-paclitaxelDrug
Administered IV
Modified FOLFIRINOXDrug
Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV
RMC-6236Drug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Dose Limiting Toxicities (DLT)Time frame: Up to 28 days
- Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)Time frame: Up to approximately 2 years
- Number of Participants Experiencing Serious Adverse Events (SAE)Time frame: Up to approximately 2 years
Locations
77 sites in 16 countries. Site status is shown where the registry gives one.
Comprehensive Blood and Cancer Center
Bakersfield, California
City of Hope National Medical Center
Duarte, California
City of Hope Orange County Lennar Foundation Cancer Center
Duarte, California
University of California San Diego Moores Cancer Center
La Jolla, California
Translational Research in Oncology US Inc, Trio Central Pharmacy
Los Angeles, California
University of California Los Angeles
Santa Monica, California
Rocky Mountain Cancer Centers
Aurora, Colorado
Hartford Hospital
Hartford, Connecticut
Yale University
New Haven, Connecticut
Norwalk Hospital
Norwalk, Connecticut
University of Chicago
Chicago, Illinois
Indiana University
Indianapolis, Indiana
Norton Cancer Institute
Louisville, Kentucky
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Washington University
St Louis, Missouri
University of Nebraska
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University
Durham, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
United States Oncology Regulatory Affairs Corporate Office
Nashville, Tennessee
Oncology Consultants Cancer Center
Houston, Texas
US Oncology Research Investigational Products Center
Irving, Texas
University of Virginia Cancer Center
Charlottesville, Virginia
Virginia Cancer Specialists PC
Fairfax, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
Northwest Medical Specialties, PLLC
Tacoma, Washington
Northwest Cancer Specialists - Vancouver
Vancouver, Washington
Chris OBrien Lifehouse
Camperdown, New South Wales, Australia
GenesisCare -North Shore Oncology
St Leonards, New South Wales, Australia
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Austin Health, Austin Hospital
Heidelberg, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Epworth Healthcare
St Albans, Victoria, Australia
Universite Catholique de Louvain Cliniques Universitaires Saint Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
Leuven, Belgium
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.